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http://www.lipidworld.com/content/13/1/21RESEARCH Open AccessApolipoprotein E polymorphism is associated
with lower extremity deep venous thrombosis:
color-flow Doppler ultrasound evaluation
ShuangLi Zhu1,2, ZhiGang Wang1*, XiaoPing Wu3, Yan Shu3 and DunXiang Lu2Abstract
Introduction: Apolipoprotein E (apoE) is a member of apolipoprotein family, and its gene polymorphisms seem to
have some impact among patients with cardiovascular disease. However, its role in the lower extremity deep
venous thrombosis (LEDVT) has not been well studied. The objective of this study was to investigate the potential
association between APOE gene polymorphisms and LEDVT.
Materials and methods: A hospital-based case–control study was conducted in 300 patients with LEDVT by
color-flow Doppler ultrasound and 300 age- and gender-matched healthy controls. Polymerase chain reaction
restriction fragment length polymorphism (PCR-RFLP) assay was applied to assess the APOE gene polymorphisms.
Results: Patients with LEDVT had a significantly higher frequency of APOE E3/E4 genotype [odds ratio (OR) =1.48,
95% confidence interval (CI) = 1.05, 2.10; P = 0.03] than healthy controls. When stratifying by family history of LEDVT,
it was found that patients with positive family history of LEDVT had a significantly higher frequency of APOE E3/E4
genotype (OR =1.68, 95% CI = 1.04, 0.95; P = 2.70). When stratifying by smoking status, presence of varicose veins, type
2 diabetes mellitus and any hormone administration before, no significant differences were found in any groups.
Conclusion: Our study suggested that APOE E3/E4 genotype was associated with a higher LEDVT risk. Additional
studies are needed to confirm this finding.
Keywords: Apolipoprotein E, Gene polymorphism, Lower extremity deep venous thrombosis, Case–control studyIntroduction
The lower extremity deep venous thrombosis (LEDVT)
and its complications remain a finding of high incidence
in hospitalized patients [1]. The use of color-flow Doppler
ultrasound has achieved a higher accuracy in diagnosis
of LEDVT than clinical examination alone [1,2]. The
advantages of color-flow Doppler ultrasound have also
provided conditions to restart investigations concerning
the incidence of bilateral LEDVT in patients with a single
symptomatic limb [1,3]. LEDVT is a multifactorial medical
problem with genetic and acquired risk factors playing in
concert in its pathogenesis [4-8]. Strong genetic factors
have been implicated in the aetiology of LEDVT [9,10].* Correspondence: zgwangzg@hotmail.com
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stated.Apolipoprotein E (apoE) is a member of apolipoprotein
family. APOE gene, located on the long arm of chromo-
some 19, codes for a 299-amino acid protein (apoE). ApoE
is a polymorphic glycoprotein involved in cholesterol
transport and cell membrane maintenance and repair
[11,12]. APOE exists in three common allelic forms: E2,
E3, and E4, giving six possible genotypes (E2/E2, E2/E3,
E2/E4, E3/E3, E3/E4 and E4/E4) [13-15]. APOE gene
polymorphisms seem to have some impact among patients
with cardiovascular disease [16-18].
Recently, a few studies with different results were per-
formed to investigate the association between APOE gene
polymorphisms and DVT [19,20]. However, its role in the
LEDVT has not been well studied. The objective of this
study was to investigate the potential association between
APOE gene polymorphisms and LEDVT.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 The demographical and clinical features of the
participants
LEDVT HC P
Total no. 300 300
Gender (Male/female) 190/110 185/115 0.67
Age (Year) 51.7 ± 10.7 52.0 ± 11.9 0.75
Smoking status (Ever/never) 122/178 116/184 0.62
Presence of varicose veins (YES/NO) 72/228 55/245 0.09
Type 2 diabetes mellitus (YES/NO) 25/275 14/286 0.07
Any hormone administration before
(YES/NO)
30/270 18/282 0.07
Family history of LEDVT (Positive/negative) 58/242 - -
LEDVT, lower extremity deep venous thrombosis; HC, healthy control.
Table 2 Frequencies of APOE gene polymorphisms in
LEDVT and HC groups
Genotype LEDVT n (%) HC n (%) OR (95% CI) P
E2/E2 3(1.0) 2(0.7) 1.51(0.25,9.07) 0.66
E2/E3 1(0.3) 2(0.7) 0.50(0.05,5.53) 0.57
E2/E4 1(0.3) 2(0.7) 0.50(0.05,5.53) 0.57
E3/E3 185(61.7) 206(68.7) 0.73(0.52,1.03) 0.07
E3/E4 105(35.0) 80(26.6) 1.48(1.05,2.10) 0.03
E4/E4 5(1.7) 8(2.6) 0.62(0.20,1.91) 0.40
E2 allele frequency 8(1.3) 8(1.3) 1.00(0.37,2.68) 1.00
E3 allele frequency 476(79.3) 494(82.3) 0.82(0.62,1.10) 0.19
E4 allele frequency 116(19.3) 98(16.3) 1.23(0.91,1.65) 0.18
LEDVT, lower extremity deep venous thrombosis; HC, healthy control; OR, odds
ratio; CI, confidence interval.
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Study population
A hospital-based case–control study was conducted in
300 patients with LEDVT and 300 age- and gender-
matched healthy controls during the years 2010 to 2013
from the institute of ultrasound imaging in the second
affiliated hospital of Chongqing Medical University, China.
The diagnosis of LEDVT was made by combining the
results of color-flow Doppler ultrasound, D-dimer levels,
and phlebography. To confirm the diagnosis, two physicians
reviewed the hospital records and validated each case. The
healthy control subjects were matched with the patients
for age and sex. Healthy control subjects were recruited
from the Second Affiliated Hospital of Chongqing Medical
University where they were attending a clinic for routine
examination. The Ethical Committee of the Second Affiliated
Hospital of Chongqing Medical University approved the
study protocols, and all participants gave written informed
consent according to the Declaration of Helsinki.
DNA extraction and genotyping
The commercially available Qiagen kit (QIAGEN Inc.,
Valencia, CA, USA) was used to extract DNA from periph-
eral blood leukocytes. Polymerase chain reaction restriction
fragment length polymorphism (PCR-RFLP) assay was
applied to assess the APOE gene polymorphisms. Based
on the GenBank reference sequence, the PCR primers
were as follows: sense, ACAGAATTCGCCCCGGCCTG
GTACAC; antisense, TAAGCTTGGCACGGCTGTCCA
AGGA. The amplified DNA was digested with Hha I at
37°C for 2 hours, and analyzed by 6% polyacrylamide gel
electrophoresis (PAGE). For quality control, all genotyping
personnel were blinded to clinical and imaging data.
Statistical analysis
The allele and genotype frequencies of APOE gene in
patients were compared to controls by Chi-square test.
The P value of statistical significance was adjusted by
Fisher’s exact test where appropriate. We applied multi-
variate logistic regression to calculate crude and adjusted
odds ratios (OR) and 95% confidence intervals (CI) for
the association between the APOE genotypes and LEDVT
risk. The Hardy–Weinberg equilibrium was tested for
goodness-of-fit chi-square test with one degree of freedom
to compare the observed genotype frequencies among
the subjects with the expected genotype frequencies. A
P-value was considered significant at a level of < 0.05.
All analyses were performed with Stata software (College
Park,Tex.).
Results
The demographical and clinical features of the participants
were showed in Table 1. The mean age was 51.7 (±10.7)
years for the LEDVT cases and 52.0 (±11.9) years for thecontrols. The 63.3% participants were male for the
LEDVT cases and 61.7% for the controls. No significant
differences were found between the patients and the
controls in gender, age, smoking status, presence of
varicose veins, type 2 diabetes mellitus and any hormone
administration before (Table 1).
Patients with LEDVT had a significantly higher frequency
of APOE E3/E4 genotype (OR =1.48, 95% CI = 1.05,
2.10; P = 0.03) than healthy controls (Table 2). When
stratifying by family history of LEDVT, it was found
that patients with positive family history of LEDVT had
a significantly higher frequency of APOE E3/E4 genotype
(OR =1.68, 95% CI = 1.04, 0.95; P = 2.70) (Table 3). When
stratifying by smoking status, presence of varicose veins,
type 2 diabetes mellitus and any hormone administration
before, no significant differences were found in any groups
(Table 3).Discussion
Many studies have been performed to investigate an
association of genetic polymorphism and DVT. A case–
control study found that subjects carrying endothelial
Table 3 Stratification analysis of APOE genotype frequency in LEDVT patients
Variable Cases
E2/E2 E2/E3 E2/E4 E3/E3 E3/E4 E4/E4
n (%) P n (%) P n (%) P n (%) P n (%) P n (%) P
Smoking status 300 3(1.0) 1(0.3) 1(0.3) 185(61.7) 105(35.0) 5(1.7)
Ever 122 1(0.8) 0.86 0(0) 0.90 0(0) 0.90 71(58.2) 0.74 48(39.3) 0.57 2(1.6) 0.98
Never 178 2(1.1) 0.90 1(0.6) 0.71 1(0.6) 0.71 114(64.0) 0.80 57(32.0) 0.64 3(1.7) 0.99
Presence of varicose veins 300 3(1.0) 1(0.3) 1(0.3) 185(61.7) 105(35.0) 5(1.7)
YES 72 1(1.4) 0.78 0(0) 0.84 0(0) 0.84 45(62.5) 0.95 25(34.7) 0.98 1(1.4) 0.87
NO 228 2(0.9) 0.89 1(0.4) 0.85 1(0.4) 0.85 140(61.4) 0.98 80(35.1) 0.99 4(1.8) 0.94
Type 2 diabetes mellitus 300 3(1.0) 1(0.3) 1(0.3) 185(61.7) 105(35.0) 5(1.7)
YES 25 1(4.0) 0.24 0(0) 0.41 0(0) 0.41 16(64.0) 0.91 7(28.0) 0.61 1(4.0) 0.43
NO 275 2(0.7) 0.73 1(0.4) 0.95 1(0.4) 0.95 169(61.5) 0.98 98(35.6) 0.91 4(1.4) 0.84
Any hormone administration before 300 3(1.0) 1(0.3) 1(0.3) 185(61.7) 105(35.0) 5(1.7)
YES 30 1(3.3) 0.30 0(0) 0.47 0(0) 0.47 18(60.0) 0.93 9(30.0) 0.70 2(6.7) 0.11
NO 270 2(0.7) 0.74 1(0.4) 0.94 1(0.4) 0.94 167(61.9) 0.98 96(35.5) 0.92 3(1.1) 0.58
Family history of DVT 300 3(1.0) 1(0.3) 1(0.3) 185(61.7) 105(35.0) 5(1.7)
Positive 58 1(1.7) 0.64 0(0) 0.74 0(0) 0.74 22(37.9) 0.07 34(58.6) 0.04 1(1.7) 0.98
Negative 242 2(0.8) 0.84 1(0.4) 0.88 1(0.4) 0.88 163(67.4) 0.52 71(29.3) 0.32 4(1.7) 0.99
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had an increased risk of DVT [21]. The 20210 A allele of
the prothrombin gene was a common risk factor among
Swedish outpatients with verified DVT [22]. A case control
study found an excess of rare coding single-nucleotide
variants of the ADAMTS13 gene in patients with DVT
[23]. A homozygosity state for 20210A prothrombin
variant in a young woman was a cause of DVT during
pregnancy [24]. Susceptibility to DVT in North Indian
Asian patients may be associated with some variants of
nitric oxide synthase 3 (NOS3) gene [25]. A large case–
control study found that factor XIII (FXIII) 34Leu carriers
were associated with a slightly decreased DVT risk [26]. A
case control study found that genetic variants in the F11
gene were risk factors for DVT among both Whites and
Blacks [27]. A meta-analysis indicated that rs2227589 in
the SERPINC1 gene, rs13146272 in the CYP4V2 gene and
rs1613662 in the GP6 gene were risk factors for DVT
among Whites [27]. A case control study concluded that
the G534E-polymorphism of the gene encoding the factor
VII-activating protease is a risk factor for DVT [28]. A
case control study suggested that tumor necrosis factor
alpha (TNF-alpha) -308A allele was association with the
risk of DVT [29]. The rs4524 SNP in F5 was consistently
associated with DVT in 3 large case–control studies
[30]. A case control study suggested that factor V G1691A
(Leiden) and A4070G (HR2 Haplotype) polymorphisms
were independent risk factors for DVT [31,32].
The APOE gene polymorphisms were associated with
many other diseases. The E4 allele of the APOE gene
was associated with a worse lipid profile in the Brazilian
urban population [33]. In the Tunisian population theAPOE E4 appears to be only indirectly involved in the
severity of coronary artery disease [34]. E2 allele of the
APOE gene polymorphism was predictive for obesity
status in Roma minority population of Croatia [35]. A
meta-analysis included 29 studies involving 2,737 CI cases
and 2,689 controls suggested that APOE E4 allele was
associated with an increased risk of developing cerebral
infarction in Chinese population [36]. A meta-analysis of
45 studies including 13,940 cases and 16,364 controls
found that APOE gene polymorphisms were associated
with essential hypertension [37]. A meta-analysis of 28
case–control studies provided evidence for an association
between the APOE E4 allele and frontotemporal lobar
degeneration [38]. A meta-analysis of seven studies, includ-
ing 2,090 cases and 742 control suggested an association
between APOE E4 mutation and increased risk of recur-
rent pregnancy loss [39]. A meta-analysis of seven studies
with 966 patients and 1,086 controls suggested that the
APOE polymorphisms were assoated with the risk of psor-
iasis, especially E2 and E3 alleles [40]. A meta-analysis of
experimental and human studies suggested an association
between APOE gene expression and its gene polymorph-
ism with nephrotic syndrome susceptibility [41]. A meta-
analysis of 6977 subjects provides evidence that APOE E2
mutation is associated with multiple sclerosis risk [42]. A
meta-analysis of 29 studies included 1,763 cases and 4,534
controls provided evidence for an association between
APOE gene polymorphisms and the risk of vascular de-
mentia [43]. A meta-analysis of 17 studies, including 1,773
cases and 2,751 controls, revealed that APOE gene E4 al-
lele was a risk factor of gallbladder stone disease, especially
in elder people and Chinese population [44].
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of all, this is a hospital based case control study, so the
selection bias cannot be avoidable and the subjects may
not be representative of the general population. Second,
the sample size of this study is relatively small, which
may not have enough statistical power to explore the real
association. Third, these results should be interpreted with
caution because the population was only from China,
which reduces the possibility of confounding from eth-
nicity, so it does not permit extrapolation of the results
to other ethnic groups.
Conclusion
In conclusion, our study suggested that APOE E3/E4
genotype was associated with a higher LEDVT risk. When
stratifying by family history of LEDVT, it was found that
patients with positive family history of LEDVT had a
significantly higher frequency of APOE E3/E4 genotype.
Additional studies are needed to confirm this finding.
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